MBX
MBX Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.48
+5.79%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$49.70
From 52W high−25.77%
Volume521769.00
Market cap$2.53B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$49.70
From 52W high
−25.77%
Volume
521769.00
Market cap
$2.53B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−19.6x
P/E (TTM)
—
RSI (14)
42.5
MomentumView details →
1D Return
+5.79%
YTD Return
+66.82%
SummaryUpdated Jun 1, 2026
MBX Biosciences, Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Carmel, Indiana. The company specializes in developing precision peptide therapies targeting endocrine and metabolic disorders, with a focus on creating long-acting hormone replacement and metabolic treatments. Since going public in 2000, MBX has built a pipeline of innovative peptide-based drug candidates designed to address unmet medical needs in conditions such as chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity.
Similar companies
Latest newsMore news →
MBX Biosciences appointed Jeff Held as Chief Legal Officer, effective as announced on September 8, 2026.42d agoMBX Biosciences dosed the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for adults with hypoparathyroidism, building on positive Phase 2 results and durable one-year clinical benefit.54d agoMBX Biosciences reported a net loss of $37.1 million for Q2 2026, compared to a net loss of $19.4 million in Q2 2025, with cash and marketable securities of $418.6 million as of June 30, 2026.75d ago